News overview
News
30 June 2022
Vidi Grants awarded to Miao-Ping Chien, Rebekka Schneider, Tineke Lenstra and Monique Mulder
Oncode Institute is proud to announce that three Oncode Investigators and one Oncode Researcher will receive a Vidi Grant worth 800.000 euros. This grant will enable Oncode Investigators Miao-Ping Chien, Rebekka Schneider (both Erasmus MC), Tineke Lenstra (Netherlands Cancer Institute) and Oncode Researcher Monique Mulder (Leiden UMC) to develop their own innovative line of research and set up their own research group in the coming five years.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
27 June 2022
Prostate cancer hijacks tumor cell biorhythm to evade hormone therapy
Hormone therapy is successful at keeping metastatic prostate cancer under control, but eventually the tumor cells become resistant to it. An unexpected potential solution has now emerged in medicines not designed to fight cancer, but to target proteins that regulate a cell’s circadian rhythm. Oncode Investigator Wilbert Zwart and others publish about this discovery in cancer discovery today.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
21 June 2022
Cell-free DNA biomarkers can help to identify treatment responders and non-responders of head and neck cancer patients
The team of Jeroen de Ridder finalized a Clinical Proof of Concept (CPoC) study in which they tested the feasibility of circulating tumor DNA (ctDNA) analysis in head- and neck cancer patients as treatment response identifier. Their results are promising and more extensive validation in larger patient cohorts is underway.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
3 June 2022
2021: Running at Full Capacity
Oncode Institute is proud to present the 2021 edition of its Annual Progress Report.
Vesnade Jong
<span>Vesna</span><span>de Jong</span>
Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
News
30 May 2022
Fully booked: Masterclass Nuclear organization in development and disease
Oncode Investigators Elzo de Wit and Ruud Delwel recently organized a well-attended Masterclass on nuclear organization in development and disease.
Vesnade Jong
<span>Vesna</span><span>de Jong</span>
Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
News
10 May 2022
Cancer Research UK forms strategic alliance with Oncode Institute
Cancer Research UK, the world’s largest private funder of cancer research, today announces a strategic alliance with Oncode Institute. The five-year partnership is the first under Cancer Research UK’s new innovation organisation, Cancer Research Horizons, as well as being Oncode’s first UK partner. The alliance aims to foster innovation and collaboration between world-leading cancer researchers.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
In the spotlight
25 April 2022
Interview on Oncode-PACT: De-risking the preclinical phase
Although Dutch fundamental cancer research is among the world’s best, findings in this area rarely result in viable cancer medicines. How should this be improved? Oncode’s Managing Director Alain Kummer, Oncode Business Development expert Emil Pot and Friso Smit, business development manager of the Utrecht Science Park, reflect on this issue, with reference to the Oncode-PACT* Growth Fund proposal. They co-created this proposal with many other stakeholders.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
6 May 2022
A new critical regulator of interferon signaling discovered
The group of Oncode Investigator Daniel Peeper (NKI) has published in Nature Communications its discovery of a new regulator of interferon γ (IFNγ signaling. The IFNγ response pathway is associated with response to immunotherapy in cancer.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
4 May 2022
Simmunext: where immunotherapy and chemistry meet
Simmunext is a company name made of three words describing the innovative approach Oncode Investigator Carl Figdor has developed to create polymers which can act as artificial antigen-presenting cells to stimulate the immune system to obtain a therapeutic response. The company is now ready for its journey to leverage this platform technology to bring novel cancer therapies to the clinic.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
News
3 May 2022
In memoriam: Joop Kroes
We received the sad news that Joop Kroes passed away last month. Joop was one of the first patient representatives of Oncode’s Clinical Advisory Board (CAB). He has always been full of enthusiasm for the CAB and Oncode’s Clinical Proof of Concept Programme.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
News
29 April 2022
Missing enzyme identified: how MATCAP works and affects brain development
Oncode Investigator Thijn Brummelkamp’s lab (NKI) previously identified Vasohibins as detyrosinating enzymes, but most cells contain detyrosinated microtubules even when the two Vasohibin genes are deleted. The team now identified MATCAP as a new enzyme involved in this process. Together with Oncode Investigator Anastassis Perrakis’ lab (NKI) they then showed how MATCAP works and how it engages with microtubules.
Bianca-OliviaNita
<span>Bianca-Olivia</span><span>Nita</span>
Scroll for more